Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Integrated control strategies for schistosomiasis japonica in Northern Samar
ACTRN12619001048178Phase 3Completed
- Sponsor
- Griffith University
- Start
- Jun 2012
- Modality
- Small Molecules, Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of praziquantel, niclosamide, SjCTPI vaccine and VacSIM in schistosomiasis and schistosomiasis japonica (6 arms), sponsored by Griffith University. Primary endpoint: Human incidence of schistosomiasis. Started Jun 2012; status: completed.
02
Drugs
praziquantelniclosamideSjCTPI vaccineVacSIM
03
Conditions
schistosomiasisschistosomiasis japonica
Beyond the preview
Go deeper on ACTRN12619001048178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001048178.